Consolidated Condensed Statements of Operations (Unaudited) - USD ($) shares in Millions, $ in Millions |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2025 |
Jun. 30, 2024 |
Jun. 30, 2025 |
Jun. 30, 2024 |
|
| Income Statement [Abstract] | ||||
| Revenue (Note 2) | $ 15,557.7 | $ 11,302.8 | $ 28,286.2 | $ 20,070.8 |
| Costs, expenses, and other: | ||||
| Cost of sales | 2,447.8 | 2,170.2 | 4,672.0 | 3,843.7 |
| Research and development | 3,336.1 | 2,711.2 | 6,069.8 | 5,234.0 |
| Marketing, selling, and administrative | 2,753.0 | 2,117.3 | 5,221.8 | 4,069.5 |
| Acquired in-process research and development (Note 3) | 153.8 | 154.3 | 1,725.5 | 264.8 |
| Asset impairment, restructuring, and other special charges (Note 5) | 0.0 | 435.0 | 35.0 | 435.0 |
| Other–net, (income) expense (Note 12) | 90.6 | 197.6 | 329.6 | 170.5 |
| Costs, expenses, and other | 8,781.3 | 7,785.6 | 18,053.7 | 14,017.5 |
| Income before income taxes | 6,776.4 | 3,517.2 | 10,232.5 | 6,053.3 |
| Income taxes (Note 8) | 1,115.9 | 550.2 | 1,812.7 | 843.4 |
| Net income | $ 5,660.5 | $ 2,967.0 | $ 8,419.8 | $ 5,209.9 |
| Earnings per share: | ||||
| Basic (in dollars per share) | $ 6.30 | $ 3.29 | $ 9.37 | $ 5.78 |
| Diluted (in dollars per share) | $ 6.29 | $ 3.28 | $ 9.35 | $ 5.76 |
| Shares used in calculation of earnings per share: | ||||
| Basic (in shares) | 897.9 | 900.9 | 898.3 | 900.8 |
| Diluted (in shares) | 899.8 | 904.2 | 900.2 | 904.0 |
| X | ||||||||||
- Definition Cost Of Sales, Operating Expenses, And Other-net No definition available.
|
| X | ||||||||||
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of restructuring charges, remediation cost, and asset impairment loss. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|